Monday, October 14, 2019 11:41:42 AM
ADMS= TRADING SIGNIFICANTLY under Cash plus Phase 3 readout imminent for a MEGA Drug with peak sales potential north of $500 million
Market Cap $106 m -- Cash $160 M --Parkinson Drug marketed -- Phase 3 readout of MS walking trial imminen (this Quarter) -- Namzaric (alzheimer´s dementia ) starting to receive royalties in may 2020 from Allergan = MASSIVE UNDERPRICED low float gem if phase 3 outcome is positive stock likely exploding to $10++ . STRONG BUY
Presentation
http://ir.adamaspharma.com/static-files/882038bd-aa87-458c-83c1-bba24c90550e
"INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) enrollment" completed, with topline results expected late Q4 2019
"Adamas Pharmaceuticals is eligible to receive royalties on net sales of Namzaric beginning in May of 2020."
Market Cap $106 m -- Cash $160 M --Parkinson Drug marketed -- Phase 3 readout of MS walking trial imminen (this Quarter) -- Namzaric (alzheimer´s dementia ) starting to receive royalties in may 2020 from Allergan = MASSIVE UNDERPRICED low float gem if phase 3 outcome is positive stock likely exploding to $10++ . STRONG BUY
Presentation
http://ir.adamaspharma.com/static-files/882038bd-aa87-458c-83c1-bba24c90550e
"INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) enrollment" completed, with topline results expected late Q4 2019
"Adamas Pharmaceuticals is eligible to receive royalties on net sales of Namzaric beginning in May of 2020."
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
